Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 575

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 3
Chunk 575
---
 stock options.

Recently
Issued Accounting Pronouncements

Certain
recently issued accounting pronouncements are discussed in Note 2, Significant Accounting Policies, to the consolidated financial statements
included in Item 8. “Financial Statements and Supplementary Data” of this Annual Report.

Item
7A. Quantitative and Qualitative Disclosures About Market Risk.

We
are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise
required under this Item 7A.

70

Item
8. Financial Statements and Supplementary Data.

INDAPTUS
THERAPEUTICS, INC.

CONSOLIDATED
FINANCIAL STATEMENTS

TABLE
OF CONTENTS

    Page
  
    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB name: HASKELL & WHITE LLP and PCAOB ID: 200)
     
    F-2
  
    CONSOLIDATED
    FINANCIAL STATEMENTS:

    Consolidated Balance Sheets as of December 31, 2024 and 2023
     
    F-3
  
    Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023
     
    F-4
  
    Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2024 and 2023
     
    F-5
  
    Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023
     
    F-6
  
    Notes to the Consolidated Financial Statements
     
    F-7

F-1

REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To
the Stockholders and Board of Directors

Indaptus
Therapeutics, Inc.

Opinion
on the Consolidated Financial Statements 

We
have audited the accompanying consolidated balance sheets of Indaptus Therapeutics, Inc. (the “Company”) as of December 31,
2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for
each of the years then ended, and the related notes (collectively, the “consolidated financial statements”). In our opinion,
the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as
of December 31, 2024 and 2023, and the consolidated results of its